Published in Br J Pharmacol on November 01, 2005
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol (2012) 1.63
Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats. Addict Biol (2011) 1.17
The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology (2006) 1.03
The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress (2010) 0.99
The vasopressin 1b receptor and the neural regulation of social behavior. Horm Behav (2011) 0.90
Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist. J Neuroendocrinol (2010) 0.79
Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour. Curr Top Behav Neurosci (2014) 0.77
Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325. Br J Pharmacol (2014) 0.76
Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist. Br J Pharmacol (2013) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques (1996) 2.60
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry (2002) 1.89
CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci (2001) 1.79
Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J (1973) 1.68
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A (2002) 1.57
Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol (1993) 1.54
Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol (2000) 1.51
Oxytocin antagonists: clinical and scientific considerations. Exp Physiol (2001) 1.46
Anxiety and stress responses in female oxytocin deficient mice. J Neuroendocrinol (2004) 1.41
Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept (2000) 1.39
OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science (1991) 1.34
Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology (2003) 1.32
Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A (1995) 1.31
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein alpha-subunit chimeras. Yeast (2000) 1.24
Release of oxytocin in the rat central amygdala modulates stress-coping behavior and the release of excitatory amino acids. Neuropsychopharmacology (2005) 1.21
Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology (2001) 1.20
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol (1992) 1.19
Aggregation of human blood platelets by vasopressin. Am J Physiol (1972) 1.19
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther (2002) 1.16
AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol Biochem Behav (2004) 1.01
Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol (1998) 0.98
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem (1995) 0.98
An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev (2001) 0.94
Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology (2005) 0.92
Neurohypophyseal hormone receptor systems in brain and periphery. Prog Brain Res (1987) 0.91
Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J Biol Chem (1996) 0.90
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res (1998) 0.90
Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun (1994) 0.87
The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord (2003) 0.87
Vasopressin receptors. A historical survey. Adv Exp Med Biol (1998) 0.86
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology (2002) 0.86
Vasopressin as a target for antidepressant development: an assessment of the available evidence. J Affect Disord (2002) 0.86
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency. Bioorg Med Chem Lett (1999) 0.86
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem (2004) 0.82
Progress in the development of oxytocin antagonists for use in preterm labor. Adv Exp Med Biol (1995) 0.82
Orally active, nonpeptide oxytocin antagonists. J Med Chem (1992) 0.81
Analysis of Apparent Noncompetitive Responses to Competitive H(1)-Histamine Receptor Antagonists in Fluorescent Imaging Plate Reader-Based Calcium Assays. J Biomol Screen (1999) 0.80
Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Investig Drugs (2001) 0.79
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet (2006) 3.88
CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat (2008) 2.66
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Mental health policy development and implementation in four African countries. J Health Psychol (2007) 2.45
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
American Academy of Orthopaedic Surgeons Clinical Practice Guideline on: optimizing the management of rotator cuff problems. J Bone Joint Surg Am (2012) 2.20
The implications of shortages of health professionals for maternal health in sub-saharan Africa. Reprod Health Matters (2006) 2.16
A code of best practice for disease control programmes to avoid damaging health care services in developing countries. Int J Health Plann Manage (2003) 2.01
WHO and partners launch Ebola response plan. Lancet (2014) 1.90
Time to failure after rotator cuff repair: a prospective imaging study. J Bone Joint Surg Am (2013) 1.76
The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain (2007) 1.73
A study of the clinical and radiological features in a cohort of 93 patients with a COL2A1 mutation causing spondyloepiphyseal dysplasia congenita or a related phenotype. Am J Med Genet A (2015) 1.60
Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome. Europace (2013) 1.56
Minimal clinically important differences in ASES and simple shoulder test scores after nonoperative treatment of rotator cuff disease. J Bone Joint Surg Am (2010) 1.50
NapA protects Helicobacter pylori from oxidative stress damage, and its production is influenced by the ferric uptake regulator. J Med Microbiol (2003) 1.45
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43
Measurement of Resource Utilization for Total and Reverse Shoulder Arthroplasty. Am J Orthop (Belle Mead NJ) (2015) 1.40
Role of Neisseria meningitidis luxS in cell-to-cell signaling and bacteremic infection. Infect Immun (2002) 1.36
Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet (2008) 1.34
"True" sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol (2002) 1.31
Propionibacterium acnes colonization of the human shoulder. J Shoulder Elbow Surg (2009) 1.27
Stickler syndrome caused by COL2A1 mutations: genotype-phenotype correlation in a series of 100 patients. Eur J Hum Genet (2010) 1.27
Inverse relationship between bioconcentration factor and exposure concentration for metals: implications for hazard assessment of metals in the aquatic environment. Environ Toxicol Chem (2003) 1.25
Frontometaphyseal dysplasia: mutations in FLNA and phenotypic diversity. Am J Med Genet A (2006) 1.20
Muscarinic receptors induce LTD of NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95. Nat Neurosci (2010) 1.16
Can malaria be controlled where basic health services are not used? Trop Med Int Health (2006) 1.14
Patients' preoperative expectations predict the outcome of rotator cuff repair. J Bone Joint Surg Am (2007) 1.14
Next-generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation. Am J Hum Genet (2012) 1.14
Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer (2008) 1.13
Parental insertional balanced translocations are an important cause of apparently de novo CNVs in patients with developmental anomalies. Eur J Hum Genet (2011) 1.11
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen (2013) 1.08
Optimizing the management of rotator cuff problems. J Am Acad Orthop Surg (2011) 1.06
SALL1 mutation analysis in Townes-Brocks syndrome: twelve novel mutations and expansion of the phenotype. Hum Mutat (2005) 1.05
Disintegrated care: the Achilles heel of international health policies in low and middle-income countries. Int J Integr Care (2006) 1.03
Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides (2006) 1.03
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther (2011) 1.03
Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem (2007) 1.03
Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol (2006) 1.02
Evaluation of a syndromic surveillance for the early detection of outbreaks among military personnel in a tropical country. J Public Health (Oxf) (2008) 1.02
1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2007) 1.02
Quality standards for health care delivery and management in publicly oriented health services. Int J Health Plann Manage (2003) 1.02
Initial fixation strength of transosseous-equivalent suture bridge rotator cuff repair is comparable with transosseous repair. Am J Sports Med (2011) 1.01
A genome-wide association study of recipient genotype and medium-term kidney allograft function. Clin Transplant (2013) 1.00
Patients with workers' compensation claims have worse outcomes after rotator cuff repair. J Bone Joint Surg Am (2008) 1.00
Early outcome of arthroscopic rotator cuff repair: a matched comparison with mini-open rotator cuff repair. Arthroscopy (2007) 1.00
Balanced into array: genome-wide array analysis in 54 patients with an apparently balanced de novo chromosome rearrangement and a meta-analysis. Eur J Hum Genet (2011) 1.00
Growth deficiencies of Neisseria meningitidis pfs and luxS mutants are not due to inactivation of quorum sensing. J Bacteriol (2008) 0.98
Health policy processes in Vietnam: a comparison of three maternal health case studies. Health Policy (2010) 0.98
First implication of STRA6 mutations in isolated anophthalmia, microphthalmia, and coloboma: a new dimension to the STRA6 phenotype. Hum Mutat (2011) 0.98
Traumatic anterosuperior rotator cuff tears: the outcome of open surgical repair. J Bone Joint Surg Am (2008) 0.97
Different susceptibility to social defeat stress of BalbC and C57BL6/J mice. Behav Brain Res (2010) 0.97
Ebola emergency meeting establishes new control centre. Lancet (2014) 0.97
Uganda battles Marburg fever outbreak. Lancet (2012) 0.96
NFAT-3 is a transcriptional repressor of the growth-associated protein 43 during neuronal maturation. J Biol Chem (2009) 0.94
Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat (2010) 0.94
UBE2A deficiency syndrome: Mild to severe intellectual disability accompanied by seizures, absent speech, urogenital, and skin anomalies in male patients. Am J Med Genet A (2010) 0.93
Brachial plexus blocks for upper extremity orthopaedic surgery. J Am Acad Orthop Surg (2012) 0.93
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology (2007) 0.93
Agonist-induced desensitization and endocytosis of heterodimeric GABAB receptors in CHO-K1 cells. Eur J Pharmacol (2003) 0.92
Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. Cancer Lett (2009) 0.91
Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment. Brain Res (2004) 0.91
Perrault syndrome: further evidence for genetic heterogeneity. J Neurol (2011) 0.91
Subscapularis tendon tears. J Am Acad Orthop Surg (2005) 0.90
Overutilization of shoulder magnetic resonance imaging as a diagnostic screening tool in patients with chronic shoulder pain. J Shoulder Elbow Surg (2005) 0.90
The contribution and challenges of electives in the development of social accountability in medical students. Med Teach (2011) 0.90
The effect of comorbidity on self-assessed function in patients with a chronic rotator cuff tear. J Bone Joint Surg Am (2004) 0.90
Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways. Life Sci (2012) 0.89
The accuracy of subjective clinical assessments of the patellar reflex. Muscle Nerve (2012) 0.89
Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse. Pharmacol Biochem Behav (2010) 0.89
Influence of comorbidity on self-assessment instrument scores of patients with idiopathic adhesive capsulitis. J Bone Joint Surg Am (2002) 0.89
Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: a time-course study in the rat. Physiol Behav (2007) 0.89
Susceptibility of young sheep to oral infection with bovine spongiform encephalopathy decreases significantly after weaning. J Virol (2012) 0.89
Functional outcomes and general health status after ulnohumeral arthroplasty for primary degenerative arthritis of the elbow. J Shoulder Elbow Surg (2006) 0.87
Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. Biochem J (2004) 0.86
Transient forebrain over-expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice. Pharmacol Biochem Behav (2009) 0.86
Exclusion, inequity and health system development: the critical emphases for maternal, neonatal and child health. Bull World Health Organ (2005) 0.86
A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics (2004) 0.86
CRF1 receptor activation increases the response of neurons in the basolateral nucleus of the amygdala to afferent stimulation. Front Behav Neurosci (2008) 0.86
Initial fixation strength of massive rotator cuff tears: in vitro comparison of single-row suture anchor and transosseous tunnel constructs. Arthroscopy (2007) 0.85
Falciparum malaria: an outbreak in a military population on an operational deployment. Mil Med (2003) 0.85
Factors influencing patient satisfaction after rotator cuff repair. J Shoulder Elbow Surg (2007) 0.85
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. J Med Chem (2008) 0.85
Critical loads of metals and other trace elements to terrestrial environments. Environ Sci Technol (2007) 0.84
Pyridine-3-carboxamides as novel CB(2) agonists for analgesia. Bioorg Med Chem Lett (2008) 0.84
Fighting restricts access to health care in South Sudan. Lancet (2014) 0.84
Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: relevance to human psychopathology. Psychoneuroendocrinology (2009) 0.84
Experts sceptical about Nigeria's free health-care plans. Lancet (2016) 0.84
A review of modern management of lateral epicondylitis. Phys Sportsmed (2012) 0.84
CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology (2012) 0.83
Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus. Brain Res (2005) 0.83
Angiotensin II type 2 receptor gene is not responsible for familial vesicoureteral reflux. J Urol (2002) 0.83
Health care in South Sudan at a crossroads. Lancet (2012) 0.82
Effect of medical comorbidity on self-assessed pain, function, and general health status after rotator cuff repair. J Bone Joint Surg Am (2006) 0.82
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. J Clin Pathol (2012) 0.81
Familial vesicoureteral reflux: influence of sex on prevalence and expression. J Urol (2006) 0.81